Rituximab therapy for life-threatining immune hemolytic anemia in a liver tranplant recipient: a case report

Transplantation Proceedings
M AkyildizY Tokat

Abstract

Rituximab an anti-CD20 chimeric monoclonal antibody directed against the CD20 antigen on B lymphocytes, has been demonstrated to be highly effective for B-cell depletion. Because of its biological properties, it has become as a treatment option for a variety of autoimmune diseases. We report successful treatment of a 25-year-old male cadaveric liver retransplant recipient who displayed severe immune hemolytic anemia with rituximab, despite no previous response to corticosteroids plus intravenous immune globulin therapy.

Citations

Sep 9, 2008·World Journal of Gastroenterology : WJG·Sumihito TamuraMasatoshi Makuuchi
Mar 28, 2008·Wiener klinische Wochenschrift·Peter Valent, Klaus Lechner
Jan 24, 2007·Liver International : Official Journal of the International Association for the Study of the Liver·Sumihito TamuraMasatoshi Makuuchi
May 31, 2007·Ophthalmic Research·C TappeinerA Heiligenhaus
May 12, 2009·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Randeep KashyapMark Orloff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. Discover the latest research on AIHA here.

Autoimmune Lymphoproliferative Syndrome

Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder of abnormal lymphocyte survival caused by defective Fas mediated apoptosis. Discover the latest research on ALPS here.